The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Inclusion Criteria: Inclusion criteria for patients with nAMD * A diagnosis of nAMD * Patient aged ≥50 years * Patients for whom the decision to initiate treatment with intravitreal (IVT) aflibercept 8 mg according to a local product information was made as part of routine clinical practice * Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws) Inclusion criteria for patients with DME * A diagnosis of DME * Patient aged ≥18 years (or country's legal age of adulthood if the legal age is \>18 years) with type 1 or type 2 diabetes mellitus * Patients for whom the decision to initiate treatment with IVT aflibercept 8 mg according to a local product information was made as part of routine clinical practice * Signed informed patient consent before the start of data collection (according to the requirements of the local authorities and laws) Exclusion Criteria: Exclusion criteria for all patients with nAMD * Participation in an investigational program with interventions outside of clinical routine practice * Contraindications as listed in the local intravitreal aflibercept 8 mg local product information * Extra/periocular infection or inflammation in either eye at time of first injection * Patient receiving other intravitreal treatments other than aflibercept in the fellow eye * Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information Additional exclusion criteria for treatment-naïve patients with nAMD * Any prior ocular treatment in the study eye or systemic treatment in nAMD Additional exclusion criteria for pretreated patients with nAMD * Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days * Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months * Fluocinolone implant in the study eye within the last 3 years * Dexamethasone implant in the study eye within the last 6 months * Any concurrent drug releasing implant in the study eye Exclusion criteria for all patients with DME * Participation in an investigational program with interventions outside of clinical routine practice * Contraindications as listed in the intravitreal aflibercept 8 mg local product information * Extra/periocular infection or inflammation in either eye at time of first injection * Patient receiving other intravitreal treatments other than aflibercept in the fellow eye * Any medication interfering with aflibercept 8 mg in the intravitreal aflibercept 8 mg local product information * Previous treatment of the study eye with laser in the last 90 days prior to first IVT aflibercept 8 mg Additional exclusion criteria for treatment-naïve patients with DME * Any prior ocular treatment in the study eye or systemic treatment in DME Additional exclusion criteria for pretreated patients with DME * Prior intravitreal anti-VEGF treatments in the study eye within the last 28 days * Prior treatment with intravitreal corticosteroid in the study eye within the last 3 months * Fluocinolone implant in the study eye within the last 3 years * Dexamethasone implant in the study eye within the last 6 months * Any concurrent drug releasing implant in the study eye